Human Immune Responses to Yellow Fever Vaccination
Primary Purpose
Yellow Fever
Status
Recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Yellow Fever Virus Vaccine
Sponsored by
About this trial
This is an interventional basic science trial for Yellow Fever focused on measuring Yellow fever, Vaccine, Immunity, Yellow fever vaccine, CD8 T cell responses
Eligibility Criteria
Inclusion Criteria:
- Able to understand and give informed consent
- Age 18-45 years or greater than or equal to 55 years
- If possible, participants agree not to take any vaccines within 30 days before or 30 days after yellow fever vaccination
- Women of child bearing potential must agree to use effective birth control throughout the duration of the study. A negative urine pregnancy test must be documented prior to vaccination.
Exclusion Criteria:
- Travel to or having lived in a country/area which is endemic for yellow fever
- History of previous yellow fever, West Nile, Dengue, St. Louis encephalitis, Japanese encephalitis vaccination or infection
- Any history of allergy to eggs, chicken or gelatin or to any previous vaccine
- A history of a medical condition resulting in impaired immunity (such as HIV infection, cancer, particularly leukemia, lymphoma, use of immunosuppressive or antineoplastic drugs or X-ray treatment). Persons with previous skin cancers or cured non-lymphatic tumors are not excluded from the study.
- History of HIV infection, Hepatitis B or Hepatitis C infection
- History of any chronic medical conditions that are considered progressive (ex, diabetes, heart disease, lung disease, liver disease, kidney disease, gastrointestinal diseases and uncontrolled hypertension). Use of systemic immunosuppressive medications (ex, prednisone) for 2 weeks or more in the past 3 months
- History of excessive alcohol consumption, drug abuse, psychiatric conditions, social conditions or occupational conditions that in the opinion of the investigator would preclude compliance with the trial
- Thymus gland problems (such as myasthenia gravis, DiGeorge syndrome, thymoma) or removal of thymus gland or history of autoimmune disorder.
- Recipient of a blood products or immune globulin product within 42 days of the vaccination visit
- Pregnant women and nursing mothers or women who are planning to become pregnant for the study duration
- Any condition in the opinion of the investigator that would interfere with the proper conduct of the trial
Sites / Locations
- The Hope Clinic of the Emory Vaccine CenterRecruiting
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Yellow Fever Virus Vaccine
Arm Description
Participants receiving the yellow fever virus vaccine
Outcomes
Primary Outcome Measures
Change in Magnitude of YFV-specific T Cell Responses
The characterization of yellow fever vaccine (YFV-17D) specific adaptive immune response will be examined as the magnitude of YFV-specific T cell responses. The schedule of follow up visits depends on if participants test positive for human leukocyte antigen (HLA) A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Change in Quality of YFV-specific T Cell Responses
The characterization of yellow fever vaccine (YFV-17D) specific adaptive immune response will be examined as the quality of YFV-specific T cell responses. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Change in Magnitude of YFV-specific Antibody Secreting Cells
The characterization of yellow fever vaccine (YFV-17D) specific adaptive immune response will be examined as the magnitude of YFV-specific antibody secreting cells. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Change in Quality of YFV-specific Antibody Secreting Cells
The characterization of yellow fever vaccine (YFV-17D) specific adaptive immune response will be examined as the quality of YFV-specific antibody secreting cells. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Change in Magnitude of YFV-specific Memory B Cells
The characterization of yellow fever vaccine (YFV-17D) specific adaptive immune response will be examined as the magnitude of YFV-specific memory B cells. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Change in Quantity of YFV-specific Memory B Cells
The characterization of yellow fever vaccine (YFV-17D) specific adaptive immune response will be examined as the quantity of YFV-specific memory B cells. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Change in Peripheral Blood Mononuclear Cell (PBMC) Cytokines
To determine the signatures of innate immune responses, cytokines on peripheral blood mononuclear cells (PBMCs) will be examined. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Change in PBMC Chemokines
To determine the signatures of innate immune responses, chemokines on PBMCs will be examined. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Change in PBMC Dendritic Cells
To determine the signatures of innate immune responses, dendritic cells on PBMCs will be examined. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Change in PBMC Gene Expression
To determine the signatures of innate immune responses, microarray analyses for gene expression on PBMCs will be performed. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Secondary Outcome Measures
Change in Characterization of Epstein-Barr Virus (EBV)
Characterization of EBV cluster of differentiation 8 (CD8) T cells will be performed. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Change in Phenotypic Analysis of Epstein-Barr Virus (EBV)
Phenotypic analysis of EBV CD8 T cells will be performed. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Change in Characterization of Cytomegalovirus (CMV)
Characterization of CMV CD8 T cells will be performed. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Change in Phenotypic Analysis of Cytomegalovirus (CMV)
Phenotypic analysis of CMV CD8 T cells will be performed. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Change in Characterization of YFV
Characterization of YFV CD8 T cells will be performed. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Change in Phenotypic Analysis of YFV
Phenotypic analysis of YFV CD8 T cells will be performed. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Full Information
NCT ID
NCT00694655
First Posted
May 19, 2008
Last Updated
November 30, 2022
Sponsor
Emory University
Collaborators
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID)
1. Study Identification
Unique Protocol Identification Number
NCT00694655
Brief Title
Human Immune Responses to Yellow Fever Vaccination
Official Title
Human Immune Responses to Yellow Fever Vaccination
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 2008 (undefined)
Primary Completion Date
December 2025 (Anticipated)
Study Completion Date
December 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Emory University
Collaborators
National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The goal of this study is to use the live attenuated yellow fever vaccine, YFV-17D (YF-VAX®, Sanofi-Pasteur) as a safe and effective model for viral infection to understand human immune response to viral antigens. Study participants will receive the yellow fever vaccine and participation in the study may be as short as one month or as long as one year, depending on immune responses.
Detailed Description
Yellow fever is a viral disease that is transmitted to humans through the bite of an infected mosquito. Yellow fever is a life-threatening infection that can result in hepatitis, renal failure and coagulation abnormalities, and in severe cases, death. Yellow fever was a major public health threat in the colonial United States in the 18th and 19th centuries.
Yellow fever is endemic in over 40 countries, and approximately 125 countries require proof of vaccination for entry by travelers at risk. An estimated 200,000 cases of yellow fever occur annually in South America and Africa, making it an important vaccine-preventable disease among travelers to endemic areas. Yellow fever can be prevented by vaccination with the yellow fever vaccine (YFV-17D). Currently, the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) recommend yellow fever vaccination for persons ≥ 9 months of age who are traveling to or living in a yellow fever endemic area.
The YFV-17D vaccine is considered to be one of the safest and most effective viral vaccines ever developed. YFV-17D vaccine is known to stimulate broad-spectrum immune responses, including cytotoxic T cells, and Th1 and Th2 responses, as well as neutralizing antibody titers that can persist for up to 30 years, after a single vaccination. Despite the great success of this empiric vaccine, there has been relatively little understanding of the mechanisms by which YFV-17D induces such robust protective immune responses. The researchers hope to apply the best contemporary methods in immunology, genomics, and proteomics to characterize in detail a successful immune response to YFV-17D vaccination. This characterization should identify new immunologic predictors that could serve as surrogates for future vaccine efficacy studies. In addition, these findings could guide development of a safer yellow fever vaccine (or the derivation of safer alternative vaccination regimens using the currently available vaccine).
This study plans to recruit both travelers to yellow fever endemic areas as well as non-travelers for participation. Participants will be followed for up to 360 days post-vaccination.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Yellow Fever
Keywords
Yellow fever, Vaccine, Immunity, Yellow fever vaccine, CD8 T cell responses
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Yellow Fever Virus Vaccine
Arm Type
Other
Arm Description
Participants receiving the yellow fever virus vaccine
Intervention Type
Biological
Intervention Name(s)
Yellow Fever Virus Vaccine
Other Intervention Name(s)
YF-VAX, YFV-17D Yellow Fever Vaccine
Intervention Description
Participants will receive the FDA-approved YFV-17D vaccine, at the FDA approved dose and route of administration.
Primary Outcome Measure Information:
Title
Change in Magnitude of YFV-specific T Cell Responses
Description
The characterization of yellow fever vaccine (YFV-17D) specific adaptive immune response will be examined as the magnitude of YFV-specific T cell responses. The schedule of follow up visits depends on if participants test positive for human leukocyte antigen (HLA) A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Time Frame
Day 0 (day of vaccination), Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
Title
Change in Quality of YFV-specific T Cell Responses
Description
The characterization of yellow fever vaccine (YFV-17D) specific adaptive immune response will be examined as the quality of YFV-specific T cell responses. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Time Frame
Day 0 (day of vaccination), Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
Title
Change in Magnitude of YFV-specific Antibody Secreting Cells
Description
The characterization of yellow fever vaccine (YFV-17D) specific adaptive immune response will be examined as the magnitude of YFV-specific antibody secreting cells. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Time Frame
Day 0 (day of vaccination), Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
Title
Change in Quality of YFV-specific Antibody Secreting Cells
Description
The characterization of yellow fever vaccine (YFV-17D) specific adaptive immune response will be examined as the quality of YFV-specific antibody secreting cells. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Time Frame
Day 0 (day of vaccination), Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
Title
Change in Magnitude of YFV-specific Memory B Cells
Description
The characterization of yellow fever vaccine (YFV-17D) specific adaptive immune response will be examined as the magnitude of YFV-specific memory B cells. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Time Frame
Day 0 (day of vaccination), Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
Title
Change in Quantity of YFV-specific Memory B Cells
Description
The characterization of yellow fever vaccine (YFV-17D) specific adaptive immune response will be examined as the quantity of YFV-specific memory B cells. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Time Frame
Day 0 (day of vaccination), Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
Title
Change in Peripheral Blood Mononuclear Cell (PBMC) Cytokines
Description
To determine the signatures of innate immune responses, cytokines on peripheral blood mononuclear cells (PBMCs) will be examined. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Time Frame
Day 0 (day of vaccination), Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
Title
Change in PBMC Chemokines
Description
To determine the signatures of innate immune responses, chemokines on PBMCs will be examined. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Time Frame
Day 0 (day of vaccination), Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
Title
Change in PBMC Dendritic Cells
Description
To determine the signatures of innate immune responses, dendritic cells on PBMCs will be examined. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Time Frame
Day 0 (day of vaccination), Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
Title
Change in PBMC Gene Expression
Description
To determine the signatures of innate immune responses, microarray analyses for gene expression on PBMCs will be performed. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Time Frame
Day 0 (day of vaccination), Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
Secondary Outcome Measure Information:
Title
Change in Characterization of Epstein-Barr Virus (EBV)
Description
Characterization of EBV cluster of differentiation 8 (CD8) T cells will be performed. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Time Frame
Day 0 (day of vaccination), Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
Title
Change in Phenotypic Analysis of Epstein-Barr Virus (EBV)
Description
Phenotypic analysis of EBV CD8 T cells will be performed. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Time Frame
Day 0 (day of vaccination), Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
Title
Change in Characterization of Cytomegalovirus (CMV)
Description
Characterization of CMV CD8 T cells will be performed. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Time Frame
Day 0 (day of vaccination), Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
Title
Change in Phenotypic Analysis of Cytomegalovirus (CMV)
Description
Phenotypic analysis of CMV CD8 T cells will be performed. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Time Frame
Day 0 (day of vaccination), Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
Title
Change in Characterization of YFV
Description
Characterization of YFV CD8 T cells will be performed. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Time Frame
Day 0 (day of vaccination), Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
Title
Change in Phenotypic Analysis of YFV
Description
Phenotypic analysis of YFV CD8 T cells will be performed. The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
Time Frame
Day 0 (day of vaccination), Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Able to understand and give informed consent
Age 18-45 years
If possible, participants agree not to take any vaccines within 30 days before or 30 days after yellow fever vaccination
Women of child bearing potential must agree to use effective birth control throughout the duration of the study. A negative urine pregnancy test must be documented prior to vaccination.
Exclusion Criteria:
Lived in a country/area which is endemic for yellow fever
History of previous yellow fever, West Nile, Dengue, St. Louis encephalitis, Japanese encephalitis vaccination or infection
Any history of allergy to eggs, chicken or gelatin or to any previous vaccine
A history of a medical condition resulting in impaired immunity (such as HIV infection, cancer, particularly leukemia, lymphoma, use of immunosuppressive or antineoplastic drugs or X-ray treatment). Persons with previous skin cancers or cured non-lymphatic tumors are not excluded from the study.
History of HIV infection, Hepatitis B or Hepatitis C infection
History of any chronic medical conditions that are considered progressive (ex, diabetes, heart disease, lung disease, liver disease, kidney disease, gastrointestinal diseases and uncontrolled hypertension). Use of systemic immunosuppressive medications (ex, prednisone) for 2 weeks or more in the past 3 months
History of excessive alcohol consumption, drug abuse, psychiatric conditions, social conditions or occupational conditions that in the opinion of the investigator would preclude compliance with the trial
Thymus gland problems (such as myasthenia gravis, DiGeorge syndrome, thymoma) or removal of thymus gland or history of autoimmune disorder
Recipient of a blood products or immune globulin product within 42 days of the vaccination visit
Pregnant women and nursing mothers or women who are planning to become pregnant for the study duration
Any condition in the opinion of the investigator that would interfere with the proper conduct of the trial
Received the second coronavirus disease 2019 (COVID-19) vaccine less than 21 days before receiving the Yellow Fever Vaccine.
COVID-19 infection in the last 60 days. Symptoms of COVID-19 symptoms must be completely resolved before yellow fever vaccine receipt.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Srilatha Edupuganti, MD, MPH
Phone
404-712-1370
Email
sedupug@emory.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rafi Ahmed, PhD
Organizational Affiliation
Emory University
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Sri Edupuganti, MD, MPH
Organizational Affiliation
Emory University
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Hope Clinic of the Emory Vaccine Center
City
Decatur
State/Province
Georgia
ZIP/Postal Code
30030
Country
United States
Individual Site Status
Recruiting
12. IPD Sharing Statement
Plan to Share IPD
No
Links:
URL
http://www.medicine.emory.edu/id/hopeclinic
Description
website for vaccine research clinic
Learn more about this trial
Human Immune Responses to Yellow Fever Vaccination
We'll reach out to this number within 24 hrs